Halo Elevate Officially Hits Shelves at Pet Supplies Plus
Halo’s Ground-Breaking Brand of Super Premium, Natural Pet Food will be Available at 600+ Pet…
News
Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO),…
LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations
PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a…
Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress
LAWRENCEVILLE, N.J., April 12, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on…
Enzo Biochem Reports Results of its Annual Meeting of Shareholders
FOR IMMEDIATE RELEASE All Four Proposals Approved NEW YORK, NY, April 12, 2022 (GLOBE NEWSWIRE)…
Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight
– Live moderated video webcast fireside chat with Dr. Klaus Paulini, CEO and Giuliano La…
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
NEWTON, Mass. and GENEVA, April 12, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER)…
Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral
CC-42344 administered orally as a single 100 mg or 200 mg dose in healthy adults…
Caladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney Disease
BASKING RIDGE, N.J., April 12, 2022 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius”…
ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT®
Two Phase 3 controlled trials with substantially similar design to enroll 1,200 subjects with diabetic…
Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias
SEATTLE, April 12, 2022 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company…
Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis
Molecular Assemblies has pioneered Fully Enzymatic Synthesis™ (or FES™) technology with an in-process purification step…
Nautilus Biotechnology Appoints Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent Development
Former Microsoft and SomaLogic executives join senior leadership team of company developing platform for comprehensively…
Aquestive Therapeutics Reports Positive Topline Data from Part 2 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
Mean Baseline Adjusted Epinephrine Concentration over Time by Treatment, 0-2h Mean Baseline Adjusted Epinephrine Concentration…
MediWound’s EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022
The poster, featuring the phase 2 pharmacology study promising results, was selected and featured during…
PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting
Presentation evaluates the addition of D-PLEX₁₀₀ to the surgical site infection standard of care prophylaxis…
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives
SYDNEY, Australia, April 12, 2022 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), the Company…
Tilray Brands Announces Definitive Agreement With Hexo Corp. Related to Hexo’s Senior Secured Convertible Note
— Canada’s Top Two Cannabis Market Leaders to Join Forces, Strengthening Operations and Unlocking up…
AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer
– Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy…
Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome
TriTAC-XR demonstrates extended release mechanism that confirms accumulation of active drug which improves therapeutic index…